BRAIN Biotech AG announced that it is extending its proprietary genome-editing toolbox with the addition of BRAIN-Metagenome-Cas 01 (BMC01) nuclease. In comparison to the publically recognized BRAIN-Engineered Cas (BEC), the BMC01 nuclease has a differentiated protein structure and mode of action to target DNA. BMC01 has already been filed for IP protection. This additional nuclease will extend BRAIN's proprietary genome editing competence and further enhance the overall economic potential of the platform, in case patent protection is granted.